This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Ludwig Institute for Cancer Research
MedImmune LLC
Xcovery Holding Company, LLC
Cancer Research Institute, New York City
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research Identifier:
First received: September 8, 2016
Last updated: March 2, 2017
Last verified: March 2017

This is an open-label, multicenter, single-arm study to evaluate the safety and preliminary efficacy of a targeted therapy for NSCLC in combination with a checkpoint inhibitor:

  • Ensartinib (X-396), an anaplastic lymphoma kinase (ALK) Inhibitor and
  • Durvalumab (MEDI4736), an anti-programmed cell death ligand 1 (PD-L1) antibody.

Condition Intervention Phase
Non-small Cell Lung Cancer Carcinoma NSCLC Drug: Ensartinib Drug: Durvalumab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of ALK Inhibitor, Ensartinib (X-396), and Anti-PD-L1, Durvalumab (MEDI4736), in Subjects With ALK-rearranged (ALK-positive) Non-small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by Ludwig Institute for Cancer Research:

Primary Outcome Measures:
  • Number of Adverse Events [ Time Frame: up to 17 months ]
    Clinical laboratory tests, vital signs and weight measurements, physical exams, ECG, Eastern Cooperative Oncology Group (ECOG) performance status evaluation, imaging scans and any other medically indicated assessments, including subject interviews, will be performed to detect new abnormalities and deterioration of any preexisting conditions. The Investigator will evaluate any laboratory abnormalities for clinical significance, and clinically significant abnormalities will be recorded as adverse events. All treatment-emergent clinically significant abnormalities and deterioration from time of signing the informed consent to the end of study visit will be recorded in the Case Report Forms (CRFs) as adverse events and graded according to the CTCAE Version 4.03.

Secondary Outcome Measures:
  • Progression Free Survival Rate [ Time Frame: up to 24 weeks ]
  • Response Rate [ Time Frame: up to 24 weeks ]
  • Overall Best Response [ Time Frame: up to 48 weeks ]
  • Disease Control Rate (DCR) [ Time Frame: up to 48 weeks ]
  • Duration of Response (DoR) [ Time Frame: up to 48 weeks ]
  • Progression Free Survival (PFS) [ Time Frame: up to 5 years ]
  • Overall Survival [ Time Frame: up to 5 years ]

Estimated Enrollment: 32
Actual Study Start Date: March 1, 2017
Estimated Study Completion Date: December 2023
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Esartinib monotherapy

There will be a run-in period where ensartinib will be given as monotherapy for 2 cycles.

Subjects who do not qualify for combination treatment may continue on monotherapy.

Drug: Ensartinib
Other Name: X-396
Experimental: Combination Treatment
Subjects who qualify for combination treatment will receive ensartinib (X-396) by mouth daily and durvalumab (MEDI4736) intravenously every 4 weeks.
Drug: Ensartinib
Other Name: X-396
Drug: Durvalumab
Other Name: MEDI4736


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic confirmation of metastatic non-small cell lung cancer (NSCLC) and confirmed ALK rearrangement.
  • Measurable disease according to RECIST 1.1.
  • Availability of archival (diagnostic) specimens and willing to undergo a pre-treatment biopsy.
  • Subjects with treated brain metastases must have been treated with surgery and/or radiation therapy ≥ 21 days pre-study and must be clinically stable.
  • Laboratory parameters for vital functions should be in the normal range or not clinically significant.
  • Body weight > 30 kilograms.

Exclusion Criteria:

  • Treatment with an investigational agent within 4 weeks of starting treatment.
  • Prior treatment with anti-PD-1, PD-L1, or CTLA4, or ensartinib (X-396).
  • Active, suspected or prior documented autoimmune disease.
  • Subjects with clinically significant cardiovascular disease.
  • History of pneumonitis or interstitial lung disease, or any unresolved immune-related adverse events.
  • Major surgery within 4 weeks of starting treatment.
  • Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.
  • History of allogenic organ transplant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02898116

Contact: Kristen Aufiero 212-450-1515

United States, Florida
Research Facility Not yet recruiting
Tampa, Florida, United States, 33612
United States, New York
Research Facility Recruiting
New York, New York, United States, 10016
Sponsors and Collaborators
Ludwig Institute for Cancer Research
MedImmune LLC
Xcovery Holding Company, LLC
Cancer Research Institute, New York City
Study Chair: Leena Gandhi, MD, PhD Laura & Isaac Perlmutter Cancer Center
  More Information

Responsible Party: Ludwig Institute for Cancer Research Identifier: NCT02898116     History of Changes
Other Study ID Numbers: LUD2014-012-ALK
Study First Received: September 8, 2016
Last Updated: March 2, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Ludwig Institute for Cancer Research:
ALK Inhibitor

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017